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Abstract Unsafe abortion continues to be a major contributor to maternal
mortality and morbidity around the world. This article examines the role of
pharmacists in expanding women’s access to safe medical abortion in Latin
America, Africa, and Asia. Available research shows that although pharmacists
and pharmacy workers often sell abortion medications to women, accurate
information about how to use the medications safely and effectively is rarely
offered. No publication covered effective interventions by pharmacists to expand
access to medical abortion, but lessons can be learned from successful interventions
with other reproductive health services. To better serve women, increasing
awareness and improving training for pharmacists and pharmacy workers about
unsafe abortion – and medications that can safely induce abortion – are needed.
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Introduction
Worldwide, women endure almost 22 million unsafe abortions each
year, defined by the World Health Organization (WHO) as ‘a procedure
for terminating an unwanted pregnancy either by persons lacking the
necessary skills or in an environment lacking the minimal medical
standards, or both’.1,2 In this article, we summarize lessons learned
from the literature about the role of pharmacists and pharmacies
in ‘medical abortion’ or pregnancy termination with medications, in
low-income settings in Latin America, Africa, and Asia, where 99 per
cent of unsafe abortions take place.1 Innovative strategies for improving
women’s access to safe abortion services are needed in these regions to
prevent morbidity and mortality in women.
Literature discussing the roles that pharmacists and pharmacy
workers play in medical abortion throughout Latin America, Africa,
and Asia provides the evidence base for this article. Two library science
experts, working independently of one another, searched PubMed and
Google Scholar, using 435 search terms. At the same time, to locate
additional literature not available through the online searches, the co-
authors contacted researchers conducting studies on pharmacies and
medical abortion in the three regions.
Medical Abortion and Pharmacies
Medical abortion is safe and effective for ending unwanted pregnancy.
Clinical studies support the combined use of mifepristone and miso-
prostol.3–5 Where mifepristone is not available, misoprostol alone can be
used as a safe and effective abortifacient.6 As of 2011, in at least
45 countries, mifepristone was registered for abortion and pending in
others;7 misoprostol was registered in more than 80 countries, primarily
for the prevention and treatment of gastric ulcers.8 The WHO includes a
mifepristone/misoprostol regimen for abortion up to 9 weeks of gesta-
tion on its Complementary Model List of Essential Medicines; miso-
prostol is included for treatment of incomplete and missed abortion.9
With greater availability of these promising drugs,8,10 pharmacists –
often first-line health-care providers in the developing world – have an
increasingly important role to play in delivering accurate information
about and increasing access to such methods. Pharmacies (also called
chemist shops and drugstores) sell medications. They are often the most
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available health-care outlet in communities.11 Pharmacy waiting times
usually are short and services, including information and direct sales of
medications, often less costly than those of other health-care provi-
ders.12–14 Trained pharmacists and pharmacy employees have success-
fully delivered care related to stigmatized health conditions, including
sexually transmitted infections (STIs), family planning, and emergency
contraception (EC). Their success has been due to their ability to facilitate
rapid access to medications, supplies, medical information, and advice
while maintaining client confidentiality.11,13,15
Despite the potential advantages of working through pharmacies,
there are challenges for ensuring accurate information and quality
care.14 In many developing countries, there are few trained professional
pharmacists; those who are well trained may not always be present in the
pharmacies where they work.13,14 Pharmacy employees, many with low
levels of education and without formal pharmacy training, sell medica-
tions without prescriptions or support from a trained health-care
professional.12,16 This often leads to inaccurate advice and incorrect
dispensing.12,14,17 The medications they sell may be unnecessary,
ineffective, or even dangerous.
Pharmacy provision of medical abortion in Africa, Asia, and
Latin America
Women seek pharmacists’ guidance when they want to end unwanted
pregnancies, both in ‘legally restrictive settings’ (where abortion
is fully illegal or is only allowed for specific reasons, such as to save
the life of the woman or in cases of rape) and in more ‘liberal settings’
(where abortion is permissible for broader health and social circumstances).
Table 1 summarizes findings from studies conducted about pharmacies and
medical abortion throughout Latin America, Africa, and Asia.
Research elucidates challenges to facilitating medical abortion through
pharmacies.
K The unwillingness of pharmacists to stock and dispense mifepristone
and/or misoprostol.
K The lack of information and knowledge about medical abortion
among pharmacy personnel, often exacerbated because misoprostol
is rarely registered or labeled for abortion. Thus, effective doses are
often unknown to pharmacists and the women seeking help.
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As Table 1 shows, pharmacy workers may be apprehensive about
informing and counseling women about abortifacients. The reasons
include: worry about risk to their employment; ethical, moral, and
religious grounds; fear of backlash from anti-abortion groups; and
Table 1: Pharmacies and medical abortion: results from research studies
Research results Restrictive settinga Liberal settingb
Country State/Country
Pharmacists/pharmacy workers do not have
correct information about how to use the
medications (mode of administration,
dosage, side effects, gestational limits)
Mexico18–20 Bihar and Jharkhand,
Indiac, 21Dominican
Republic22




uncomfortable in helping customers with
abortifacients
Mexico27 No research findings to
reportNigeria25
Kenya26
Pharmacists/pharmacy workers do not request a
prescription to sell the medication













Pharmacists/pharmacy workers willing or
unwilling to stock misoprostol and/or
mifepristone in pharmacies
Mexicoe, 18–20 Nepal28
Kenyaf , 26 Tamil Nadu, India24
Bihar and Jharkhand,
India21
Medical abortion medications are restricted to
authorized sites
Brazilg, 29 Vietnamh, 30
aRestrictive settings are where countries prohibit abortion entirely or have few exceptions to a broad
prohibition, which include saving the life of the woman or pregnancy resulting from rape.
bLiberal settings are where countries permit abortion under any circumstance without legal
penalties incurred on the woman who aborts or the provider offering abortion services.
cIn India, the Drug Controller approved the manufacture and sale of mifepristone in 2002.
dIn India and Nepal, mifepristone and misoprostol may be sold by prescription in chemist shops.
ePharmacists/pharmacy workers were willing to stock medications.
fPharmacists/pharmacy workers were unwilling to stock medications.
gIn Brazil, only hospitals may purchase misoprostol.
hVietnam limits mifepristone sales to pharmacies authorized by government (usually affiliated with
hospitals).
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perceptions that physicians, rather than pharmacy workers, should
provide such information. Even pharmacists and pharmacy workers
who were willing to provide information and sell the medicines often
gave customers incorrect or incomplete information about the route of
administration, dosages, side effects, and gestational limits for medi-
cations used for medical abortion. Some countries, such as Brazil
and Vietnam, restrict stocking and distribution of medical abortion
medications to authorized sites, thereby excluding non-hospital-based
pharmacies (Table 1).
Studies also show that pharmacists do dispense misoprostol, regard-
less of local regulations intended to prevent pharmacists from prescrib-
ing medications and that they frequently do not request a prescription. In
restrictive and liberal settings alike, pharmacists often sell medicines that
are ineffective abortifacients and may be unsafe (Table 1). In South
Asia, many pharmacists and pharmacy workers recommend allopathic,
ayurvedic, or homeopathic drugs, although their effectiveness for
abortion has not been clinically evaluated. In Latin America and Africa,
pharmacists and pharmacy workers incorrectly recommended contra-
ceptive methods, including EC, as abortifacients.
Where abortion is legally restricted, low-income women have even
more difficulty accessing safe abortion services than do women with
resources, yet medications for inducing abortion safely may be available.
Studies in Mexico, the Dominican Republic, and Argentina show that
pharmacies in low-income neighborhoods are more likely to carry
misoprostol than those in medium- to high-income areas.18,22,23
Research in four regions of Mexico showed independent privately
owned pharmacies, and those located in low-income areas, to have been
significantly more likely to sell misoprostol by the pill than chain
pharmacies and those in medium-income areas.18 Pharmacy managers
may be responding to demand generated by low-income women for a
safe and relatively inexpensive alternative to unsafe abortions.
Approaches to working with pharmacists
Although efforts have been made to extend the range and quality of
reproductive health services offered at pharmacies, including counseling,
information, and sales of medications, we found no publications about
how pharmacists can improve access to safe medical abortion. Commu-
nities, governments, non-governmental organizations, and international
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organizations have asked pharmacists and pharmacy workers to
improve access to EC, contraceptives in general, and medications for
STIs. Thus, we draw on literature from other areas of sexual and
reproductive health, including studies on interventions with other sorts
of health-care professionals, to explore the potential for expanding the
role of pharmacists in medical abortion.
Non-physician clinicians (including midwives, nurse practitioners,
clinical officers, and physician assistants) can deliver safe abortion
care.31–35 Studies demonstrate that maintaining abortion services strictly
within the confines of physician-only practices is unnecessary. Other
types of providers can offer safe and effective abortions – including
medical ones. Pharmacists, however, do not traditionally fall within the
definition of a midlevel provider or even health-care provider. Their role
as service providers or facilitators who can connect with other cadres of
providers to increase access to medical abortion has yet to be examined.
Nor have researchers yet studied the ability of pharmacists to screen
women for appropriate gestational age and lack of risk factors
(for example, ectopic pregnancy) for medical abortion.
In both liberal and restrictive settings, strategies to work with
pharmacists must take into account local policies and context; these
are often controversial or confusing. For example:
K Mifepristone and/or misoprostol may be registered in countries but
are not for sale in readily accessible pharmacies.
K Pharmacists may not be legally authorized to sell medical abortion
medications without prescriptions; these prescriptions may not be
available to lower-income women, who cannot afford to see anyone
other than a pharmacist for their care.
K Pharmacists or pharmacy workers may not be trained to advise
consumers on the correct use of medications.
K Pharmacists and pharmacy workers may have moral objections to
abortion and refuse to sell medications, even when the consumer has a
prescription.
Social marketing and detailing
Social marketing applies commercial marketing strategies to social
causes and often sells an associated product at a subsidized rate.
Developing a network of retailers to sell a specific product and thus
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increasing product promotion and distribution by raising awareness
through advertising, packaging, and branding is a typical approach.
Social marketing may also include training programs for pharmacy
personnel (often through educational outreach visits, also known as
academic or medical detailing) and development and distribution of
information, education, and communication materials for pharmacists,
pharmacy workers, and clients. Social marketing that has already been
applied to reproductive health products could likely be a successful
mechanism to enhance pharmacy staff capacity and provide quality
medications as part of a broader medical abortion strategy.36,37
A challenge of social marketing is finding ongoing support or a subsidy
for sustainability. Ultimately, products and services need to be profitable
to those who provide them, and affordable to those who need them.
A 1997 Cochrane Systematic Review on the use of academic detailing
included two studies on pharmacists and pharmacy workers. Detailing
visits included talking with pharmacists about evidence-based informa-
tion and leaving them with written information, with the objective of
improving the advice and information they offer to clients. Individua-
lized outreach visits, particularly when combined with social marketing,
did affect provider behaviors, especially prescribing. The intensity
(measured in the number of detailing visits) needed, the sustainability
of this effect over time, and cost-effectiveness, remain unknown.38,39
Pharmacists in a Kenyan study expressed preference for detailers to
offer regular updates to pharmacy staff on the use of emergency
contraceptives. They viewed the visits as a good method for reminding
pharmacy staff about the importance of providing clients with informa-
tion about emergency contraceptives while making the sale.40
Pharmacist training
Training of pharmacists using materials, referral links, and refresher
courses has met with some success, but without strong evidence for
longer-term impact.13,41 In Lima, Peru, an intervention study in 14 of the
city’s 24 lowest socio-economic districts showed that training pharma-
cists and physicians in STI management and linking them through a
formalized referral network strengthened the connection and commu-
nication between the two professions and improved their recommenda-
tions to clients for STI treatment regimens.15 A 1-day program in Ghana
on effective drug treatments for STIs with pharmacists resulted in better
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prescribing practices for urethral discharge.13 In Mexico City, pharmacy
workers became slightly more willing to offer information about
condoms after a training about STI treatment and HIV/AIDS prevention;
the information was more accurate than that offered by pharmacy
workers who did not participate in any training.42 The need to conduct
one-on-one training to accommodate individual schedules makes
comprehensive training expensive. Only training reinforced by refresher
sessions sustained gains long term.13,42
Health-care referral systems
Referral systems between pharmacists and other health-care providers
have helped women receive appropriate care.15 In a randomized control
trial, in a program that trained pharmacists to identify and manage
STDs, use of referral cards improved communication between pharma-
cists and physicians, facilitating continuity of care.15 In Brazil, training
pharmacy workers only to refer people to the public health system for
care was not effective, because consumers looked to pharmacies for a
solution, not simply for a referral.14
Discussion
As pharmacists and pharmacy workers often sell something to customers
to end a pregnancy, it is imperative that they learn about what is or is not
effective for medical abortion, and where to refer women who need
clinical attention. In many countries, medical abortion practice guide-
lines do not exist, thus limiting information on up-to-date drug options
and evidence-based practices. Misoprostol, moreover, does not have
package labeling for its use in abortion care. Regulations that guide
pharmacist practices may limit prescribing of medications or selling
them over-the-counter. Where medical abortion is available in some
form, programs that build referral networks among clinicians prescrib-
ing medical abortion and pharmacists who stock and sell the product
may reach more women than single-profession interventions.
Successful interventions must address what hinders pharmacists: lack
of training in counseling during pharmacy school; shortage of trained
pharmacists in pharmacies throughout the world; and client concerns
about confidentiality. Strong links with other health-care providers can
address pharmacists’ inability to confirm physical findings of pregnancy
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(beyond what a woman reports) and address complications. Because
pharmacists are often also business owners, they want to know how
expanding and improving services for women with unwanted pregnan-
cies can improve pharmacy practices and pharmacists’ livelihoods.
Conclusion
Even where pharmacists’ knowledge about medical abortion is limited,
many are willing to provide something to help a woman with an
unwanted pregnancy. Women already seek medicines from pharmacists
to end unwanted pregnancy, but some of these women are unable or
unwilling to seek care from a trained clinical provider. Approaches that
successfully improve pharmacists’ ability and willingness to provide
accurate information about medications as well as referrals to other
health-care providers can help women benefit from safe and effective
medical abortions. To date, such approaches and interventions have not
been documented. When they are, they will need to be carefully tested
and rigorously evaluated. The specific roles of pharmacists in medical
abortion will depend on a country’s legal and policy context. Research is
needed to test strategies that enable pharmacists to collaborate effec-
tively with other health-care providers and thus reduce unsafe abortions
and increase women’s access to safe abortion services.
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